ZA965650B - Treatment of arterloscierosis and xanthoma - Google Patents

Treatment of arterloscierosis and xanthoma

Info

Publication number
ZA965650B
ZA965650B ZA965650A ZA965650A ZA965650B ZA 965650 B ZA965650 B ZA 965650B ZA 965650 A ZA965650 A ZA 965650A ZA 965650 A ZA965650 A ZA 965650A ZA 965650 B ZA965650 B ZA 965650B
Authority
ZA
South Africa
Prior art keywords
dione
ylmethoxy
methoxy
xanthoma
benzylüthiazolidine
Prior art date
Application number
ZA965650A
Other languages
English (en)
Inventor
Yoshio Tsujita
Masashi Shiomi
Hiroyoshi Horikoshi
Takashi Ito
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15847039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA965650(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of ZA965650B publication Critical patent/ZA965650B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Glass Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA965650A 1995-07-03 1996-07-03 Treatment of arterloscierosis and xanthoma ZA965650B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16729195 1995-07-03

Publications (1)

Publication Number Publication Date
ZA965650B true ZA965650B (en) 1997-01-27

Family

ID=15847039

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA965650A ZA965650B (en) 1995-07-03 1996-07-03 Treatment of arterloscierosis and xanthoma

Country Status (20)

Country Link
US (2) US5798375A (es)
EP (1) EP0753298B2 (es)
KR (1) KR100424124B1 (es)
CN (1) CN1089584C (es)
AT (1) ATE209046T1 (es)
AU (1) AU706628B2 (es)
CA (1) CA2180296C (es)
CZ (1) CZ286832B6 (es)
DE (1) DE69617116T3 (es)
DK (1) DK0753298T3 (es)
ES (1) ES2165474T5 (es)
HK (1) HK1011928A1 (es)
HU (1) HUP9601808A3 (es)
IL (1) IL118778A (es)
NO (1) NO318765B1 (es)
NZ (1) NZ286920A (es)
PT (1) PT753298E (es)
RU (1) RU2158607C2 (es)
TW (1) TW474809B (es)
ZA (1) ZA965650B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
WO1998025598A2 (en) * 1996-12-11 1998-06-18 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumour cell growth
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
SI1009400T1 (en) * 1997-08-29 2005-04-30 Pfizer Inc. Combination therapy comprising atorvastatin and an antihypertensive agent
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
IL135537A (en) * 1997-10-08 2006-08-20 Daiichi Sankyo Co Ltd Melted heterocyclic compounds
DE69834508T2 (de) * 1997-11-19 2006-11-23 Takeda Pharmaceutical Co. Ltd. Apoptoseinhibitoren
US20030105154A1 (en) 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
EP1087963B1 (en) 1998-06-19 2004-08-25 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7141602B2 (en) * 1998-09-18 2006-11-28 Lek Pharmaceuticals D.D. Process for obtaining HMG-CoA reductase inhibitors of high purity
US6326396B1 (en) 1998-11-20 2001-12-04 Alteon, Inc. Glucose and lipid lowering compounds
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
TWI284533B (en) 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
DZ3218A1 (fr) 1999-10-11 2001-04-19 Pfizer Pyrimidine-7-ones 5-(2-substitutees-5-heterocyclylsulphonylpyride-3-yl)-dihydropyrazolo[4,3-d] servant d'inhibiteurs de la phosphodiesterase
EP1254667A4 (en) * 2000-02-10 2003-03-12 Takeda Chemical Industries Ltd MEDICINE COMPRISING A COMBINATION
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
WO2001076566A1 (en) * 2000-04-10 2001-10-18 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
FR2807944B1 (fr) * 2000-04-25 2003-06-13 Solvay Pharma Utilisation de l'anethole-dithiolethione dans la prevention et le traitement de la tenotoxicite induite par un medicament
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
WO2001093860A1 (en) 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
TWI284529B (en) * 2000-12-18 2007-08-01 Sankyo Co A composition for lowering triglyceride
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
WO2002051396A1 (fr) * 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions pharmaceutiques contenant des derives de cyclobutene
KR20030096294A (ko) * 2001-03-27 2003-12-24 랜박시 래보러터리스 리미티드 프라바스타틴의 안정한 약학적 조성물
US20040077689A1 (en) * 2001-04-25 2004-04-22 Yasuo Sugiyama Abc expression promoters
US6486127B1 (en) 2001-05-23 2002-11-26 Insmed, Incorporated Compositions comprising D-chiro inositol and lipid lowering compounds and methods of treatment thereof
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
WO2003026643A2 (en) * 2001-09-21 2003-04-03 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1601669B1 (en) 2003-03-07 2008-12-24 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ES2421520T3 (es) * 2003-04-28 2013-09-03 Daiichi Sankyo Co Ltd Potenciador de la producción de adiponectina
US7772272B2 (en) * 2003-04-28 2010-08-10 Daiichi Sankyo Company, Limited Method for enhancing glucose uptake into warm-blooded animal adipocytes
NZ543741A (en) 2003-05-30 2009-10-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors
WO2005000299A1 (en) * 2003-06-27 2005-01-06 Dr. Reddy's Research Foundation Compositions comprising balaglitazone and further antidiabetic compounds
US6978908B2 (en) * 2003-09-15 2005-12-27 Gerber Products Company Drinking vessel with adjustable handles
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) * 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) * 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
US8026377B2 (en) 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
EP1984026B1 (en) * 2006-01-30 2013-05-01 Ben David Bryson Israel Compositions treating cardiovascular, cerebrovascular and other vascular disease patients
CN101454005B (zh) 2006-03-16 2013-01-02 新陈代谢解决方案开发公司 用于治疗代谢性炎症介导的疾病的噻唑烷二酮类似物
CA2646149A1 (en) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
US20080051417A1 (en) * 2006-07-18 2008-02-28 Yochai Birnbaum Uses of selective cyclooxygenase-1 inhibitors
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
ES2398313T3 (es) 2007-09-14 2013-03-15 Metabolic Solutions Development Company Llc 5-(4-(2-(3-metoxifenil)-2-oxoetoxi)bencil)tiazolidin-2,4-diona para uso en el tratamiento de la diabetes
WO2011084453A1 (en) 2009-12-15 2011-07-14 Metabolic Solutions Development Company Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
AU2016348638A1 (en) 2015-11-06 2018-06-07 Gemphire Therapeutics Inc. Gemcabene combinations for the treatment of cardiovascular disease

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
AU535944B2 (en) * 1979-06-15 1984-04-12 Merck & Co., Inc. Hypocholestermic fermentation products from aspergillus
AU548996B2 (en) * 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
EP0295828A1 (en) * 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
EP0306228B1 (en) * 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US5120754A (en) * 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US4897405A (en) * 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469383A (ja) * 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd 置換チアゾリジン誘導体
GB9017218D0 (en) * 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
CA2118706A1 (en) * 1992-07-13 1994-01-20 Saizo Shibata Novel thiazolidinedione compounds and use thereof
JPH0741423A (ja) * 1993-02-24 1995-02-10 Sankyo Co Ltd 動脈硬化症治療剤
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
IL113313A (en) * 1994-04-11 1999-09-22 Sankyo Co Heterocyclic compounds and pharmaceutical compositions containing the same
CA2159938A1 (en) * 1994-10-07 1996-04-08 Hiroaki Yanagisawa Oxime derivatives, their preparation and their therapeutic use
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
KR19990087076A (ko) * 1996-04-05 1999-12-15 다께다 구니오 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는 약제학적 배합물
ATE355840T1 (de) * 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin

Also Published As

Publication number Publication date
HUP9601808A3 (en) 2000-06-28
IL118778A0 (en) 1996-10-31
EP0753298B2 (en) 2011-02-16
KR970005307A (ko) 1997-02-19
ES2165474T3 (es) 2002-03-16
CZ286832B6 (en) 2000-07-12
CN1089584C (zh) 2002-08-28
DK0753298T3 (da) 2002-05-21
DE69617116T3 (de) 2011-10-06
HK1011928A1 (en) 1999-07-23
ATE209046T1 (de) 2001-12-15
EP0753298A1 (en) 1997-01-15
PT753298E (pt) 2002-03-28
NZ286920A (en) 1997-06-24
TW474809B (en) 2002-02-01
HUP9601808A2 (en) 1997-04-28
CZ198296A3 (en) 1997-01-15
CA2180296A1 (en) 1997-01-04
RU2158607C2 (ru) 2000-11-10
IL118778A (en) 1999-07-14
NO962784L (no) 1997-01-06
ES2165474T5 (es) 2011-06-08
US5798375A (en) 1998-08-25
CN1148492A (zh) 1997-04-30
AU5626196A (en) 1997-01-16
CA2180296C (en) 2007-01-09
DE69617116T2 (de) 2002-08-29
EP0753298B1 (en) 2001-11-21
NO318765B1 (no) 2005-05-02
US6159997A (en) 2000-12-12
KR100424124B1 (ko) 2004-06-26
AU706628B2 (en) 1999-06-17
NO962784D0 (no) 1996-07-02
DE69617116D1 (de) 2002-01-03

Similar Documents

Publication Publication Date Title
ZA965650B (en) Treatment of arterloscierosis and xanthoma
RU96112769A (ru) Лечение артериосклероза и ксантомы
CA2273298A1 (en) Product and method for the treatment of hyperlipidemia
AU6959898A (en) Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
AU4614793A (en) Liquid-permeable topsheet for body fluid absorptive goods
FI945457A (fi) Testosteronin 5alfa-reduktaasiaktiviteetin inhibiittorit
EE04356B1 (et) aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis
AU5733796A (en) High-dose chromic tripicolinate for the treatment of type ii diabetes
AU2058992A (en) HMG-COA reductase inhibitors
HK1003051A1 (en) Treatment and prophylaxis of pancreatitis
AU4705193A (en) Medicaments for the treatment or prevention of elevated intraocular pressure
MY118381A (en) Statin-carboxyalkylether combinations
AU4694999A (en) Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
AU1680292A (en) Pharmaceutical combination for the treatment of prostatic cancer containing a 5 alpha reductase inhibitor and an antiandrogen
WO2001035979A3 (en) Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
AU5270693A (en) Pharmaceutical composition for preventing or treating arteriosclerosis
ZA9510970B (en) Synergistic combinations of 2-(thiocyanomethylthio) benzothiazole and thiophanate compounds useful as fungicides
TH27628B (th) การรักษาโรคผนังเส้นเลือกแดงหนาแข็งและแซนโธมา
BR9813539A (pt) Combinações de inibidor de lp(a) e estatina anti-hiperlipidêmicas
DE59813136D1 (de) Verwendung von Thiaminen zur Herstellung eines Arzneimittels zur Prophylaxe und zur Therapie der diabetischen Retinopathie und der diabetischen Nephropathie
MX9602577A (es) Tratamiento de arterioesclerosis y xantoma.
CO5611117A2 (es) Combinacion de compuestos organicos
NO932874D0 (no) Anvendelse av lacidipin for behandling av arteriosklerose
AU5970294A (en) Agents for the prevention and treatment of lesch-nyhan syndrome
WO2000007582A3 (en) Use of thiazolidinedione derivatives for the treatment or prevention of cataracts